Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.

Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0844 (Electronic) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE

Publication: 2014- : Chichester : Wiley
Original Publication: Amsterdam ; New York : Elsevier Science, c1999-

Heart Failure*/epidemiology ; Heart Failure*/therapy ; Heart Failure*/etiology ; Heart Valve Diseases*/complications ; Heart Valve Diseases*/epidemiology ; Cardiology*; Humans ; Shock, Cardiogenic/complications

Acute heart failure (AHF) represents a broad spectrum of disease states, resulting from the interaction between an acute precipitant and a patient's underlying cardiac substrate and comorbidities. Valvular heart disease (VHD) is frequently associated with AHF. AHF may result from several precipitants that add an acute haemodynamic stress superimposed on a chronic valvular lesion or may occur as a consequence of a new significant valvular lesion. Regardless of the mechanism, clinical presentation may vary from acute decompensated heart failure to cardiogenic shock. Assessing the severity of VHD as well as the correlation between VHD severity and symptoms may be difficult in patients with AHF because of the rapid variation in loading conditions, concomitant destabilization of the associated comorbidities and the presence of combined valvular lesions. Evidence-based interventions targeting VHD in settings of AHF have yet to be identified, as patients with severe VHD are often excluded from randomized trials in AHF, so results from these trials do not generalize to those with VHD. Furthermore, there are not rigorously conducted randomized controlled trials in the setting of VHD and AHF, most of the data coming from observational studies. Thus, distinct to chronic settings, current guidelines are very elusive when patients with severe VHD present with AHF, and a clear-cut strategy could not be yet defined. Given the paucity of evidence in this subset of AHF patients, the aim of this scientific statement is to describe the epidemiology, pathophysiology, and overall treatment approach for patients with VHD who present with AHF.
(© 2023 European Society of Cardiology.)

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131. https://doi.org/10.1002/ejhf.2333.
Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J. 2006;27:2725-2736. https://doi.org/10.1093/eurheartj/ehl193.
Chioncel O, Vinereanu D, Datcu M, Ionescu DD, Capalneanu R, Brukner I, et al. The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J. 2011;162:142-53.e1. https://doi.org/10.1016/j.ahj.2011.03.033.
Spinar J, Parenica J, Vitovec J, Widimsky P, Linhart A, Fedorco M, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care. 2011;15:R291. https://doi.org/10.1186/cc10584.
Oliva F, Mortara A, Cacciatore G, Chinaglia A, Di Lenarda A, Gorini M, et al.; IN-HF Outcome Investigators. Acute heart failure patient profiles, management and in-hospital outcome: Results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail. 2012;14:1208-1217. https://doi.org/10.1093/eurjhf/hfs117.
Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: The OFICA study. Eur J Heart Fail. 2013;15:465-476. https://doi.org/10.1093/eurjhf/hfs189.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123-1133. https://doi.org/10.1016/j.jacc.2013.11.053.
Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-625. https://doi.org/10.1002/ejhf.566.
Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al.; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338-1352. https://doi.org/10.1002/ejhf.1492.
Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, et al.; ICA-SEMES Research Group. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. Eur J Heart Fail. 2019;21:1353-1365. https://doi.org/10.1002/ejhf.1502.
McClung JA. Native and prosthetic valve emergencies. Cardiol Rev. 2016;24:14-18. https://doi.org/10.1097/CRD.0000000000000079.
Maheshwari V, Barr B, Srivastava M. Acute valvular heart disease. Cardiol Clin. 2018;36:115-127. https://doi.org/10.1016/j.ccl.2017.08.006.
Akodad M, Schurtz G, Adda J, Leclercq F, Roubille F. Management of valvulopathies with acute severe heart failure and cardiogenic shock. Arch Cardiovasc Dis. 2019;112:773-780. https://doi.org/10.1016/j.acvd.2019.06.009.
Jentzer JC, Ternus B, Eleid M, Rihal C. Structural heart disease emergencies. J Intensive Care Med. 2021;36:975-988. https://doi.org/10.1177/0885066620918776.
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72-e227. https://doi.org/10.1161/CIR.0000000000000923.
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632. https://doi.org/10.1093/eurheartj/ehab395.
Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, et al.; EORP VHD II Investigators. Contemporary presentation and management of valvular heart disease: The EURObservational Research Programme Valvular Heart Disease II survey. Circulation. 2019;140:1156-1169. https://doi.org/10.1161/CIRCULATIONAHA.119.041080.
Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022;24:335-350. https://doi.org/10.1002/ejhf.2408.
Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): A cohort study. Lancet Glob Health. 2020;8:e411-e422. https://doi.org/10.1016/S2214-109X(20)30004-8.
Filippatos G, Angermann CE, Cleland JGF, Lam CSP, Dahlstrom U, Dickstein K, et al. Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. JAMA Cardiol. 2020;5:401-410. https://doi.org/10.1001/jamacardio.2019.5108.
Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al.; ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242-1254. https://doi.org/10.1002/ejhf.890.
Abdurashidova T, Monney P, Tzimas G, Soborun N, Regamey J, Daux A, et al. Non-severe aortic regurgitation increases short-term mortality in acute heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7:3901-3909. https://doi.org/10.1002/ehf2.12983.
Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF. Eur J Heart Fail. 2021;23:1750-1758. https://doi.org/10.1002/ejhf.2276.
Arora S, Sivaraj K, Hendrickson M, Chang PP, Weickert T, Qamar A, et al. Prevalence and prognostic significance of mitral regurgitation in acute decompensated heart failure: The ARIC study. JACC Heart Fail. 2021;9:179-189. https://doi.org/10.1016/j.jchf.2020.09.015.
Wada Y, Ohara T, Funada A, Hasegawa T, Sugano Y, Kanzaki H, et al. Prognostic impact of functional mitral regurgitation in patients admitted with acute decompensated heart failure. Circ J. 2016;80:139-147. https://doi.org/10.1253/circj.CJ-15-0663.
Kubo S, Kawase Y, Hata R, Maruo T, Tada T, Kadota K. Dynamic severe mitral regurgitation on hospital arrival as prognostic predictor in patients hospitalized for acute decompensated heart failure. Int J Cardiol. 2018;273:177-182. https://doi.org/10.1016/j.ijcard.2018.09.093.
De la Espriella R, Santas E, Chorro FJ, Minana G, Soler M, Bodi V, et al. Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. Int J Cardiol. 2019;291:83-88. https://doi.org/10.1016/j.ijcard.2019.03.051.
Santas E, Chorro FJ, Minana G, Mendez J, Munoz J, Escribano D, et al. Tricuspid regurgitation and mortality risk across left ventricular systolic function in acute heart failure. Circ J. 2015;79:1526-1533. https://doi.org/10.1253/circj.CJ-15-0129.
Mutlak D, Lessick J, Khalil S, Yalonetsky S, Agmon Y, Aronson D. Tricuspid regurgitation in acute heart failure: Is there any incremental risk? Eur Heart J Cardiovasc Imaging. 2018;19:993-1001. https://doi.org/10.1093/ehjci/jex343.
Lancellotti P, Gerard PL, Pierard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J. 2005;26:1528-1532. https://doi.org/10.1093/eurheartj/ehi189.
Bartko PE, Hulsmann M, Hung J, Pavo N, Levine RA, Pibarot P, et al. Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. Eur Heart J. 2020;41:2799-2810. https://doi.org/10.1093/eurheartj/ehaa129.
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119. https://doi.org/10.1093/eurheartj/ehv317.
Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. Pulmonary hypertension in valvular disease: A comprehensive review on pathophysiology to therapy from the HAVEC Group. JACC Cardiovasc Imaging. 2015;8:83-99. https://doi.org/10.1016/j.jcmg.2014.12.003.
Yamamoto K, Ikeda U, Mito H, Fujikawa H, Sekiguchi H, Shimada K. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circulation. 1994;89:2093-2098. https://doi.org/10.1161/01.cir.89.5.2093.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618-3731. https://doi.org/10.1093/eurheartj/ehac237.
Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, Segovia-Cubero J, et al.; Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39:1255-1264. https://doi.org/10.1093/eurheartj/ehx700.
Tichelbacker T, Dumitrescu D, Gerhardt F, Stern D, Wissmuller M, Adam M, et al. Pulmonary hypertension and valvular heart disease. Herz. 2019;44:491-501. https://doi.org/10.1007/s00059-019-4823-6.
Al-Omary MS, Sugito S, Boyle AJ, Sverdlov AL, Collins NJ. Pulmonary hypertension due to left heart disease: Diagnosis, pathophysiology, and therapy. Hypertension. 2020;75:1397-1408. https://doi.org/10.1161/HYPERTENSIONAHA.119.14330.
Fawzy ME, Hassan W, Stefadouros M, Moursi M, El Shaer F, Chaudhary MA. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis. 2004;13(6):942-947. PMID: 15597587. (PMID: 15597587)
Le Tourneau T, Richardson M, Juthier F, Modine T, Fayad G, Polge AS, et al. Echocardiography predictors and prognostic value of pulmonary artery systolic pressure in chronic organic mitral regurgitation. Heart. 2010;96:1311-1317. https://doi.org/10.1136/hrt.2009.186486.
Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI, et al.; Mitral Regurgitation International DAtabase (MIDA) Investigators. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: A multicenter long-term international study. Eur Heart J. 2011;32:751-759. https://doi.org/10.1093/eurheartj/ehq294.
Kusunose K, Popovic ZB, Motoki H, Marwick TH. Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ Cardiovasc Imaging. 2013;6:167-176. https://doi.org/10.1161/CIRCIMAGING.112.000162.
Faggiano P, Antonini-Canterin F, Ribichini F, D'Aloia A, Ferrero V, Cervesato E, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol. 2000;85:204-208. https://doi.org/10.1016/s0002-9149(99)00643-8.
Cam A, Goel SS, Agarwal S, Menon V, Svensson LG, Tuzcu EM, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis. J Thorac Cardiovasc Surg. 2011;142:800-808. https://doi.org/10.1016/j.jtcvs.2010.12.024.
Lancellotti P, Magne J, Donal E, O'Connor K, Dulgheru R, Rosca M, et al. Determinants and prognostic significance of exercise pulmonary hypertension in asymptomatic severe aortic stenosis. Circulation. 2012;126:851-859. https://doi.org/10.1161/CIRCULATIONAHA.111.088427.
Khandhar S, Varadarajan P, Turk R, Sampat U, Patel R, Kamath A, et al. Survival benefit of aortic valve replacement in patients with severe aortic regurgitation and pulmonary hypertension. Ann Thorac Surg. 2009;88:752-756. https://doi.org/10.1016/j.athoracsur.2009.05.025.
Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol. 2002;90:1405-1409. https://doi.org/10.1016/s0002-9149(02)02886-2.
Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596. https://doi.org/10.1016/j.jacc.2008.05.068.
Topilsky Y, Khanna A, Le Tourneau T, Park S, Michelena H, Suri R, et al. Clinical context and mechanism of functional tricuspid regurgitation in patients with and without pulmonary hypertension. Circ Cardiovasc Imaging. 2012;5:314-323. https://doi.org/10.1161/CIRCIMAGING.111.967919.
Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WH, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol. 2013;62:485-495. https://doi.org/10.1016/j.jacc.2013.04.070.
Shiran A, Najjar R, Adawi S, Aronson D. Risk factors for progression of functional tricuspid regurgitation. Am J Cardiol. 2014;113:995-1000. https://doi.org/10.1016/j.amjcard.2013.11.055.
Mangieri A, Montalto C, Pagnesi M, Jabbour RJ, Rodes-Cabau J, Moat N, et al. Mechanism and implications of the tricuspid regurgitation: From the pathophysiology to the current and future therapeutic options. Circ Cardiovasc Interv. 2017;10:e005043. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005043.
Bartko PE, Arfsten H, Frey MK, Heitzinger G, Pavo N, Cho A, et al. Natural history of functional tricuspid regurgitation: Implications of quantitative Doppler assessment. JACC Cardiovasc Imaging. 2019;12:389-397. https://doi.org/10.1016/j.jcmg.2018.11.021.
Dietz MF, Prihadi EA, van der Bijl P, Goedemans L, Mertens BJA, Gursoy E, et al. Prognostic implications of right ventricular remodeling and function in patients with significant secondary tricuspid regurgitation. Circulation. 2019;140:836-845. https://doi.org/10.1161/CIRCULATIONAHA.119.039630.
Sanz J, Sanchez-Quintana D, Bossone E, Bogaard HJ, Naeije R. Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:1463-1482. https://doi.org/10.1016/j.jacc.2018.12.076.
Margonato D, Ancona F, Ingallina G, Melillo F, Stella S, Biondi F, et al. Tricuspid regurgitation in left ventricular systolic dysfunction: Marker or target? Front Cardiovasc Med. 2021;8:702589. https://doi.org/10.3389/fcvm.2021.702589.
Arden C, Chambers JB, Sandoe J, Ray S, Prendergast B, Taggart D, et al. Can we improve the detection of heart valve disease? Heart. 2014;100:271-273. https://doi.org/10.1136/heartjnl-2013-304223.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. https://doi.org/10.1093/eurheartj/ehw128.
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715-731. https://doi.org/10.1002/ejhf.1494.
Fuernau G, Desch S, de Waha-Thiele S, Eitel I, Neumann FJ, Hennersdorf M, et al. Arterial lactate in cardiogenic shock: Prognostic value of clearance versus single values. JACC Cardiovasc Interv. 2020;13:2208-2216. https://doi.org/10.1016/j.jcin.2020.06.037.
Jilaihawi H, Asch FM, Manasse E, Ruiz CE, Jelnin V, Kashif M, et al. Systematic CT methodology for the evaluation of subclinical leaflet thrombosis. JACC Cardiovasc Imaging. 2017;10:461-470. https://doi.org/10.1016/j.jcmg.2017.02.005.
Hryniewiecki T, Zatorska K, Abramczuk E, Zakrzewski D, Szymanski P, Kusmierczyk M, et al. The usefulness of cardiac CT in the diagnosis of perivalvular complications in patients with infective endocarditis. Eur Radiol. 2019;29:4368-4376. https://doi.org/10.1007/s00330-018-5965-2.
Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR): An expert consensus document of the Society of Cardiovascular Computed Tomography. JACC Cardiovasc Imaging. 2019;12:1-24. https://doi.org/10.1016/j.jcmg.2018.12.003.
Osaka S, Tanaka M. Strategy for porcelain ascending aorta in cardiac surgery. Ann Thorac Cardiovasc Surg. 2018;24:57-64. https://doi.org/10.5761/atcs.ra.17-00181.
Aviram G, Sharony R, Kramer A, Nesher N, Loberman D, Ben-Gal Y, et al. Modification of surgical planning based on cardiac multidetector computed tomography in reoperative heart surgery. Ann Thorac Surg. 2005;79:589-595. https://doi.org/10.1016/j.athoracsur.2004.07.012.
Koo HJ, Yang DH, Kang JW, Lee JY, Kim DH, Song JM, et al. Demonstration of infective endocarditis by cardiac CT and transoesophageal echocardiography: Comparison with intra-operative findings. Eur Heart J Cardiovasc Imaging. 2018;19:199-207. https://doi.org/10.1093/ehjci/jex010.
Ouchi K, Sakuma T, Ojiri H. Cardiac computed tomography as a viable alternative to echocardiography to detect vegetations and perivalvular complications in patients with infective endocarditis. Jpn J Radiol. 2018;36:421-428. https://doi.org/10.1007/s11604-018-0740-5.
Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam M, et al. Improving the diagnostic performance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in prosthetic heart valve endocarditis. Circulation. 2018;138:1412-1427. https://doi.org/10.1161/CIRCULATIONAHA.118.035032.
Ricciardi A, Sordillo P, Ceccarelli L, Maffongelli G, Calisti G, Di Pietro B, et al. 18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: An additional tool in the diagnosis of prosthetic valve endocarditis. Int J Infect Dis. 2014;28:219-224. https://doi.org/10.1016/j.ijid.2014.04.028.
Rajiah P, Fulton NL, Bolen M. Magnetic resonance imaging of the papillary muscles of the left ventricle: Normal anatomy, variants, and abnormalities. Insights Imaging. 2019;10:83. https://doi.org/10.1186/s13244-019-0761-3.
Gidwani UK, Mohanty B, Chatterjee K. The pulmonary artery catheter: A critical reappraisal. Cardiol Clin. 2013;31:545-565. https://doi.org/10.1016/j.ccl.2013.07.008.
Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1315-1341. https://doi.org/10.1002/ejhf.1922.
Lin SS, Tiong IY, Asher CR, Murphy MT, Thomas JD, Griffin BP. Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiography. Am J Cardiol. 2000;86:1097-1101. https://doi.org/10.1016/s0002-9149(00)01166-8.
Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: Diagnosis and therapeutic considerations. Heart. 2007;93:137-142. https://doi.org/10.1136/hrt.2005.071183.
Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova TV, Kutikhin AG. Degeneration of bioprosthetic heart valves: Update 2020. J Am Heart Assoc. 2020;9:e018506. https://doi.org/10.1161/JAHA.120.018506.
Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al.; EURO-ENDO Investigators. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: A prospective cohort study. Eur Heart J. 2019;40:3222-3232. https://doi.org/10.1093/eurheartj/ehz620.
Kong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, et al. Outcomes of culture-negative vs. culture-positive infective endocarditis: The ESC-EORP EURO-ENDO registry. Eur Heart J. 2022;43:2770-2780. https://doi.org/10.1093/eurheartj/ehac307.
Roux V, Salaun E, Tribouilloy C, Hubert S, Bohbot Y, Casalta JP, et al. Coronary events complicating infective endocarditis. Heart. 2017;103:1906-1910. https://doi.org/10.1136/heartjnl-2017-311624.
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al.; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307-2318. https://doi.org/10.1056/NEJMoa1806640.
Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al.; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379:2297-2306. https://doi.org/10.1056/NEJMoa1805374.
Adamo M, Fiorelli F, Melica B, D'Ortona R, Lupi L, Giannini C, et al. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation. JACC Cardiovasc Interv. 2021;14:15-25. https://doi.org/10.1016/j.jcin.2020.09.050.
Neuhold S, Huelsmann M, Pernicka E, Graf A, Bonderman D, Adlbrecht C, et al. Impact of tricuspid regurgitation on survival in patients with chronic heart failure: Unexpected findings of a long-term observational study. Eur Heart J. 2013;34:844-852. https://doi.org/10.1093/eurheartj/ehs465.
Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231-1243. https://doi.org/10.1016/s0195-668x(03)00201-x.
Andell P, Li X, Martinsson A, Andersson C, Stagmo M, Zoller B, et al. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart. 2017;103:1696-1703. https://doi.org/10.1136/heartjnl-2016-310894.
Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O, et al. Characteristics, management, and outcomes of patients with multiple native valvular heart disease: A substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. Eur Heart J. 2022;43:2756-2766. https://doi.org/10.1093/eurheartj/ehac209.
Windecker S, Okuno T, Unbehaun A, Mack M, Kapadia S, Falk V. Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation? Eur Heart J. 2022;43:2729-2750. https://doi.org/10.1093/eurheartj/ehac105.
Vahanian A, Himbert D, Brochet E. Multiple valve disease - assessment, strategy and intervention. EuroIntervention. 2015;11:W14-W16. https://doi.org/10.4244/EIJV11SWA3.
Sinning JM, Mellert F, Schiller W, Welz A, Nickenig G, Hammerstingl C. Transcatheter mitral valve replacement using a balloon-expandable prosthesis in a patient with calcified native mitral valve stenosis. Eur Heart J. 2013;34:2609. https://doi.org/10.1093/eurheartj/eht254.
Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:2998-3008. https://doi.org/10.1016/j.jacc.2019.09.028.
Okuno T, Asami M, Khan F, Praz F, Heg D, Lanz J, et al. Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement? Eur Heart J Cardiovasc Imaging. 2020;21:522-532. https://doi.org/10.1093/ehjci/jez208.
Hahn RT, Pibarot P, Otto CM. Transcatheter interventions spark a paradigm change for management of patients with mixed valve disease. Eur Heart J. 2022;43:2767-2769. https://doi.org/10.1093/eurheartj/ehac229.
Miller RR, Vismara LA, DeMaria AN, Salel AF, Mason DT. Afterload reduction therapy with nitroprusside in severe aortic regurgitation: Improved cardiac performance and reduced regurgitant volume. Am J Cardiol. 1976;38:564-567. https://doi.org/10.1016/s0002-9149(76)80003-3.
Khot UN, Novaro GM, Popovic ZB, Mills RM, Thomas JD, Tuzcu EM, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756-1763. https://doi.org/10.1056/NEJMoa022021.
Garcia-Gonzalez MJ, Jorge-Perez P, Jimenez-Sosa A, Acea AB, Lacalzada Almeida JB, Ferrer Hita JJ. Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: An interventional study. Cardiovasc Ther. 2015;33:193-199. https://doi.org/10.1111/1755-5922.12132.
Stevenson LW, Bellil D, Grover-McKay M, Brunken RC, Schwaiger M, Tillisch JH, et al. Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1987;60:654-658. https://doi.org/10.1016/0002-9149(87)90376-6.
Hamilton MA, Stevenson LW, Child JS, Moriguchi JD, Walden J, Woo M. Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. Am J Cardiol. 1991;67:259-263. https://doi.org/10.1016/0002-9149(91)90556-z.
Branzi G, Malfatto G, Villani A, Ciambellotti F, Revera M, Giglio A, et al. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. J Cardiovasc Med (Hagerstown). 2010;11:662-668. https://doi.org/10.2459/JCM.0b013e32833832f6.
Wunderlich NC, Dalvi B, Ho SY, Kux H, Siegel RJ. Rheumatic mitral valve stenosis: Diagnosis and treatment options. Curr Cardiol Rep. 2019;21:14. https://doi.org/10.1007/s11886-019-1099-7.
Iung B, Leenhardt A, Extramiana F. Management of atrial fibrillation in patients with rheumatic mitral stenosis. Heart. 2018;104:1062-1068. https://doi.org/10.1136/heartjnl-2017-311425.
Kholdani CA, Fares WH. Management of right heart failure in the intensive care unit. Clin Chest Med. 2015;36:511-520. https://doi.org/10.1016/j.ccm.2015.05.015.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075-3128. https://doi.org/10.1093/eurheartj/ehv319.
Harjola VP, Mebazaa A, Celutkiene J, Bettex D, Bueno H, Chioncel O, et al. Contemporary management of acute right ventricular failure: A statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18:226-241. https://doi.org/10.1002/ejhf.478.
Alviar CL, Miller PE, McAreavey D, Katz JN, Lee B, Moriyama B, et al. Positive pressure ventilation in the cardiac intensive care unit. J Am Coll Cardiol. 2018;72:1532-1553. https://doi.org/10.1016/j.jacc.2018.06.074.
Masip J, Peacock WF, Price S, Cullen L, Martin-Sanchez FJ, Seferovic P, et al. Indications and practical approach to non-invasive ventilation in acute heart failure. Eur Heart J. 2018;39:17-25. https://doi.org/10.1093/eurheartj/ehx580.
Balthazar T, Vandenbriele C, Verbrugge FH, Den Uil C, Engström A, Janssens S, et al. Managing patients with short-term mechanical circulatory support: JACC review topic of the week. J Am Coll Cardiol. 2021;77:1243-1256. https://doi.org/10.1016/j.jacc.2020.12.054.
Singh V, Mendirichaga R, Inglessis-Azuaje I, Palacios IF, O'Neill WW. The role of Impella for hemodynamic support in patients with aortic stenosis. Curr Treat Options Cardiovasc Med. 2018;20:44. https://doi.org/10.1007/s11936-018-0644-9.
Alkhalil A, Hajjar R, Ibrahim H, Ruiz CE. Mechanical circulatory support in transcatheter aortic valve implantation in the United States (from the National Inpatient Sample). Am J Cardiol. 2019;124:1615-1620. https://doi.org/10.1016/j.amjcard.2019.08.013.
Adamo M, Chiari E, Curello S, Maiandi C, Chizzola G, Fiorina C, et al. Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: Is it still an exclusion criterion? Eur J Heart Fail. 2016;18:1278-1286. https://doi.org/10.1002/ejhf.520.
Eliaz R, Turyan A, Beeri R, Shuvy M. Utilization of intra-aortic balloon pump to allow MitraClip procedure in patients with non-coapting mitral valve leaflets: A case series. Eur Heart J Case Rep. 2019;3:ytz045. https://doi.org/10.1093/ehjcr/ytz045.
Vandenbriele C, Balthazar T, Wilson J, Adriaenssens T, Davies S, Droogne W, et al. Left Impella®-device as bridge from cardiogenic shock with acute, severe mitral regurgitation to MitraClip®-procedure: A new option for critically ill patients. Eur Heart J Acute Cardiovasc Care. 2021;10:415-421. https://doi.org/10.1093/ehjacc/zuaa031.
Elhussein TA, Hutchison SJ. Acute mitral regurgitation: Unforeseen new complication of the Impella LP 5.0 ventricular assist device and review of literature. Heart Lung Circ. 2014;23:e100-e104. https://doi.org/10.1016/j.hlc.2013.10.098.
Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734-745. https://doi.org/10.1093/ejcts/ezs043.
Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol. 2017;70:2752-2763. https://doi.org/10.1016/j.jacc.2017.10.006.
De Backer O, Pilgrim T, Simonato M, Mackensen GB, Fiorina C, Veulemanns V, et al. Usefulness of transcatheter aortic valve implantation for treatment of pure native aortic valve regurgitation. Am J Cardiol. 2018;122:1028-1035. https://doi.org/10.1016/j.amjcard.2018.05.044.
ClinicalTrials.gov. THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study, [NCT02732704].
Achkouty G, Amabile N, Zannis K, Veugeois A, Caussin C. Transcatheter aortic valve replacement for severe aortic regurgitation with acute refractory cardiogenic shock. Can J Cardiol. 2018;34:342.e5-342.e7. https://doi.org/10.1016/j.cjca.2017.11.024.
Branca L, Adamo M, Fiorina C, Ettori F, Chizzola G, Scodro M, et al. Life-saving transcatheter aortic valve implantation for acute severe aortic regurgitation due to rheumatoid arthritis and complicated by cardiogenic shock. J Cardiovasc Med (Hagerstown). 2020;21:268-271. https://doi.org/10.2459/JCM.0000000000000873.
Adamo M, Fiorina C, Petronio AS, Giannini C, Tamburino C, Barbanti M, et al. Comparison of early and long-term outcomes after transcatheter aortic valve implantation in patients with New York Heart Association functional class IV to those in class III and less. Am J Cardiol. 2018;122:1718-1726. https://doi.org/10.1016/j.amjcard.2018.08.006.
Frerker C, Schewel J, Schluter M, Schewel D, Ramadan H, Schmidt T, et al. Emergency transcatheter aortic valve replacement in patients with cardiogenic shock due to acutely decompensated aortic stenosis. EuroIntervention. 2016;11:1530-1536. https://doi.org/10.4244/EIJY15M03_03.
Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, et al. Outcomes following urgent/emergent transcatheter aortic valve replacement: Insights from the STS/ACC TVT Registry. JACC Cardiovasc Interv. 2018;11(12):1175-1185. https://doi.org/10.1016/j.jcin.2018.03.002.
Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, et al. Demographics, procedural characteristics, and clinical outcomes when cardiogenic shock precedes TAVR in the United States. JACC Cardiovasc Interv. 2020;13:1314-1325. https://doi.org/10.1016/j.jcin.2020.02.033.
Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION (PercutAneous coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A randomized clinical trial. JACC Cardiovasc Interv. 2021;14:1965-1974. https://doi.org/10.1016/j.jcin.2021.06.041.
Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2023;19:37-52. https://doi.org/10.4244/EIJ-D-22-00958.
Williams T, Hildick-Smith DJR. Balloon aortic valvuloplasty: Indications, patient eligibility, technique and contemporary outcomes. Heart. 2020;106:1102-1110. https://doi.org/10.1136/heartjnl-2019-315904.
Debry N, Kone P, Vincent F, Lemesle G, Delhaye C, Schurtz G, et al. Urgent balloon aortic valvuloplasty in patients with cardiogenic shock related to severe aortic stenosis: Time matters. EuroIntervention. 2018;14:e519-e525. https://doi.org/10.4244/EIJ-D-18-00029.
Eugene M, Urena M, Abtan J, Carrasco JL, Ghodbane W, Nataf P, et al. Effectiveness of rescue percutaneous balloon aortic valvuloplasty in patients with severe aortic stenosis and acute heart failure. Am J Cardiol. 2018;121:746-750. https://doi.org/10.1016/j.amjcard.2017.11.048.
Bularga A, Bing R, Shah AS, Adamson PD, Behan M, Newby DE, et al. Clinical outcomes following balloon aortic valvuloplasty. Open Heart. 2020;7:e001330. https://doi.org/10.1136/openhrt-2020-001330.
Bongiovanni D, Kuhl C, Bleiziffer S, Stecher L, Poch F, Greif M, et al. Emergency treatment of decompensated aortic stenosis. Heart. 2018;104:23-29. https://doi.org/10.1136/heartjnl-2016-311037.
Chakraborty S, Patel N, Bandyopadhyay D, Hajra A, Amgai B, Zaid S, et al. Readmission following urgent transcatheter aortic valve implantation versus urgent balloon aortic valvuloplasty in patients with decompensated heart failure or cardiogenic shock. Catheter Cardiovasc Interv. 2021;98:607-612. https://doi.org/10.1002/ccd.29690.
Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: A report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol. 2000;36:1104-1109. https://doi.org/10.1016/s0735-1097(00)00846-9.
Wolff R, Cohen G, Peterson C, Wong S, Hockman E, Lo J, et al. MitraClip for papillary muscle rupture in patient with cardiogenic shock. Can J Cardiol. 2014;30:1461.e13-1461.e14. https://doi.org/10.1016/j.cjca.2014.07.015.
Bahlmann E, Frerker C, Kreidel F, Thielsen T, Ghanem A, van der Schalk H, et al. MitraClip implantation after acute ischemic papillary muscle rupture in a patient with prolonged cardiogenic shock. Ann Thorac Surg. 2015;99:e41-e42. https://doi.org/10.1016/j.athoracsur.2014.09.075.
Komatsu I, Cohen EA, Cohen GN, Czarnecki A. Transcatheter mitral valve edge-to-edge repair with the new MitraClip XTR system for acute mitral regurgitation caused by papillary muscle rupture. Can J Cardiol. 2019;35:1604.e5-1604.e7. https://doi.org/10.1016/j.cjca.2019.06.024.
McGee EC Jr. Should moderate or greater mitral regurgitation be repaired in all patients with LVEF <30%? Surgery, mitral regurgitation, and heart failure: The valves are all repairable but the patients are not. Circ Heart Fail. 2008;1:285-289. https://doi.org/10.1161/CIRCHEARTFAILURE.108.800185.
Lavall D, Hagendorff A, Schirmer SH, Bohm M, Borger MA, Laufs U. Mitral valve interventions in heart failure. ESC Heart Fail. 2018;5:552-561. https://doi.org/10.1002/ehf2.12287.
Haberman D, Taramasso M, Czarnecki A, Kerner A, Chrissoheris M, Spargias K, et al. Salvage MitraClip in severe secondary mitral regurgitation complicating acute myocardial infarction: Data from a multicentre international study. Eur J Heart Fail. 2019;21:1161-1164. https://doi.org/10.1002/ejhf.1565.
Haberman D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, Arzamendi D, Adamo M, et al. Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. Eur Heart J. 2022;43:641-650. https://doi.org/10.1093/eurheartj/ehab496.
Estevez-Loureiro R, Shuvy M, Taramasso M, Benito-Gonzalez T, Denti P, Arzamendi D, et al. Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: Effect of cardiogenic shock on outcomes (IREMMI Registry). Catheter Cardiovasc Interv. 2021;97:1259-1267. https://doi.org/10.1002/ccd.29552.
Falasconi G, Melillo F, Pannone L, Adamo M, Ronco F, Latib A, et al. Use of edge-to-edge percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: A multicenter observational experience (MITRA-SHOCK study). Catheter Cardiovasc Interv. 2021;98:E163-E170. https://doi.org/10.1002/ccd.29683.
Jung RG, Simard T, Kovach C, Flint K, Don C, Di Santo P, et al. Transcatheter mitral valve repair in cardiogenic shock and mitral regurgitation: A patient-level multicenter analysis. JACC Cardiovasc Interv. 2021;14:1-11. https://doi.org/10.1016/j.jcin.2020.08.037.
Adamo M, Curello S, Chiari E, Fiorina C, Chizzola G, Magatelli M, et al. Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. Int J Cardiol. 2017;234:53-57. https://doi.org/10.1016/j.ijcard.2017.02.072.
Estevez-Loureiro R, Adamo M, Arzamendi D, Denti P, Freixa X, Nombela-Franco L, et al. Transcatheter mitral valve repair in patients with acute myocardial infarction: Insights from the European Registry of MitraClip in Acute Mitral Regurgitation following an acute myocardial infarction (EREMMI). EuroIntervention. 2020;15:1248-1250. https://doi.org/10.4244/EIJ-D-19-00653.
Tang GHL, Estevez-Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following edge-to-edge transcatheter mitral valve repair in patients with cardiogenic shock: A nationwide analysis. J Am Heart Assoc. 2021;10:e019882. https://doi.org/10.1161/JAHA.120.019882.
Ananthakrishna Pillai A, Ramasamy C, Kottyath H. Outcomes following balloon mitral valvuloplasty in pregnant females with mitral stenosis and significant sub valve disease with severe decompensated heart failure. J Interv Cardiol. 2018;31:525-531. https://doi.org/10.1111/joic.12507.
Galusko V, Ionescu A, Edwards A, Sekar B, Wong K, Patel K, et al. Management of mitral stenosis: A systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes. 2022;8:602-618. https://doi.org/10.1093/ehjqcco/qcab083.
Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M, et al. TRI-SCORE: A new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J. 2022;43:654-662. https://doi.org/10.1093/eurheartj/ehab679.
Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, et al. Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. Eur Heart J. 2020;41:2785-2795. https://doi.org/10.1093/eurheartj/ehaa138.
Brener MI, Lurz P, Hausleiter J, Rodes-Cabau J, Fam N, Kodali SK, et al. Right ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing transcatheter tricuspid valve repair. J Am Coll Cardiol. 2022;79:448-461. https://doi.org/10.1016/j.jacc.2021.11.031.
Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al.; TRILUMINATE Pivotal Investigators. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833-1842. https://doi.org/10.1056/NEJMoa2300525.
Messika-Zeitoun D, Baumgartner H, Burwash IG, Vahanian A, Bax J, Pibarot P, et al. Unmet needs in valvular heart disease. Eur Heart J. 2023;44:1862-1873. https://doi.org/10.1093/eurheartj/ehad121.
Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention. 2021;17:791-808. https://doi.org/10.4244/EIJ-D-21-00695.
Russo G, Taramasso M, Pedicino D, Gennari M, Gavazzoni M, Pozzoli A, et al. Challenges and future perspectives of transcatheter tricuspid valve interventions: Adopt old strategies or adapt to new opportunities? Eur J Heart Fail. 2022;24:442-454. https://doi.org/10.1002/ejhf.2398.
Gelsomino S, Maessen JG, van der Veen F, Livi U, Renzulli A, Luca F, et al. Emergency surgery for native mitral valve endocarditis: The impact of septic and cardiogenic shock. Ann Thorac Surg. 2012;93:1469-1476. https://doi.org/10.1016/j.athoracsur.2011.11.025.
Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: Challenges and perspectives. Lancet. 2012;379:965-975. https://doi.org/10.1016/S0140-6736(11)60755-1.
Özkan M, Gündüz S, Güner A, Kalçık M, Gürsoy MO, Uygur B, et al. Thrombolysis or surgery in patients with obstructive mechanical valve thrombosis: The multicenter HATTUSHA study. J Am Coll Cardiol. 2022;79:977-989. https://doi.org/10.1016/j.jacc.2021.12.027.
Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, et al.; Paravalvular Leak Academic Research Consortium. Clinical trial principles and endpoint definitions for paravalvular leaks in surgical prosthesis: An expert statement. J Am Coll Cardiol. 2017;69:2067-2087. https://doi.org/10.1016/j.jacc.2017.02.038.
Raval J, Nagaraja V, Eslick GD, Denniss AR. Transcatheter valve-in-valve implantation: A systematic review of literature. Heart Lung Circ. 2014;23:1020-1028. https://doi.org/10.1016/j.hlc.2014.06.001.
Hanson ID, Dalal PK, Renard BM, Hanzel GS, Vivacqua A. Emergency valve-in-valve transcatheter aortic valve implantation for the treatment of acute stentless bioprosthetic aortic insufficiency and cardiogenic shock. Case Rep Cardiol. 2018;2018:6872748. https://doi.org/10.1155/2018/6872748.
Rufian-Andujar S, Iftikhar O, Salinger M, Saucedo J, Feldman T, Guerrero M. Transseptal transcatheter mitral valve-in-valve for treatment of severe mitral regurgitation in failed bioprosthesis complicated with cardiogenic shock: Case report and review of the literature. Cardiovasc Revasc Med. 2018;19:874-878. https://doi.org/10.1016/j.carrev.2018.02.011.
Noly PE, Pagani FD, Noiseux N, Stulak JM, Khalpey Z, Carrier M, et al. Continuous-flow left ventricular assist devices and valvular heart disease: A comprehensive review. Can J Cardiol. 2020;36:244-260. https://doi.org/10.1016/j.cjca.2019.11.022.
Bouabdallaoui N, El-Hamamsy I, Pham M, Giraldeau G, Parent MC, Carrier M, et al. Aortic regurgitation in patients with a left ventricular assist device: A contemporary review. J Heart Lung Transplant. 2018;37:1289-1297. https://doi.org/10.1016/j.healun.2018.07.002.
Cowger J, Rao V, Massey T, Sun B, May-Newman K, Jorde U, et al. Comprehensive review and suggested strategies for the detection and management of aortic insufficiency in patients with a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2015;34:149-157. https://doi.org/10.1016/j.healun.2014.09.045.
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant. 2013;32:157-187. https://doi.org/10.1016/j.healun.2012.09.013.
Robertson JO, Naftel DC, Myers SL, Tedford RJ, Joseph SM, Kirklin JK, et al. Concomitant mitral valve procedures in patients undergoing implantation of continuous-flow left ventricular assist devices: An INTERMACS database analysis. J Heart Lung Transplant. 2018;37:79-88. https://doi.org/10.1016/j.healun.2017.09.016.
Coyan GN, Pierce BR, Rhinehart ZJ, Ruppert KM, Katz W, Kilic A, et al. Impact of pre-existing mitral regurgitation following left ventricular assist device implant. Semin Thorac Cardiovasc Surg. 2021;33:988-995. https://doi.org/10.1053/j.semtcvs.2020.12.007.
Kanwar MK, Rajagopal K, Itoh A, Silvestry SC, Uriel N, Cleveland JC Jr, et al. Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial. J Heart Lung Transplant. 2020;39:529-537. https://doi.org/10.1016/j.healun.2020.03.003.
Maltais S, Topilsky Y, Tchantchaleishvili V, McKellar SH, Durham LA, Joyce LD, et al. Surgical treatment of tricuspid valve insufficiency promotes early reverse remodeling in patients with axial-flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2012;143:1370-1376. https://doi.org/10.1016/j.jtcvs.2011.07.014.
Dunlay SM, Deo SV, Park SJ. Impact of tricuspid valve surgery at the time of left ventricular assist device insertion on postoperative outcomes. ASAIO J. 2015;61:15-20. https://doi.org/10.1097/MAT.0000000000000145.
Mendiola Pla M, Chiang Y, Nicoara A, Poehlein E, Green CL, Gross R, et al. Surgical treatment of tricuspid valve regurgitation in patients undergoing left ventricular assist device implantation: Interim analysis of the TVVAD trial. J Thorac Cardiovasc Surg. https://doi.org/10.1016/j.jtcvs.2022.10.054 Published online ahead of print 16/11/22.
Trankle CR, Gertz ZM, Koneru JN, Kasirajan V, Nicolato P, Bhardwaj HL, et al. Severe tricuspid regurgitation due to interactions with right ventricular permanent pacemaker or defibrillator leads. Pacing Clin Electrophysiol. 2018;41:845-853. https://doi.org/10.1111/pace.13369.
Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, et al. Outcomes of TTVI in patients with pacemaker or defibrillator leads: Data from the TriValve registry. JACC Cardiovasc Interv. 2020;13:554-564. https://doi.org/10.1016/j.jcin.2019.10.058.
Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a palliative approach into heart failure care: A European Society of Cardiology Heart Failure Association position paper. Eur J Heart Fail. 2020;22:2327-2339. https://doi.org/10.1002/ejhf.1994.
Brannstrom M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: A randomized controlled study. Eur J Heart Fail. 2014;16:1142-1151. https://doi.org/10.1002/ejhf.151.
Sidebottom AC, Jorgenson A, Richards H, Kirven J, Sillah A. Inpatient palliative care for patients with acute heart failure: Outcomes from a randomized trial. J Palliat Med. 2015;18:134-142. https://doi.org/10.1089/jpm.2014.0192.

Keywords: Acute heart failure; Management; Valvular heart disease

Date Created: 20230613 Date Completed: 20230809 Latest Revision: 20230809

20230809

10.1002/ejhf.2918

37312239